We found that patients in the high-risk group were resistant to anti-CTLA4/PD-1/PD-L1 therapy, and we also validated the stability of CRSS-predicted immunotherapy in additional immunotherapy datasets, including urothelial tumors (IMvigor210) and high-grade melanoma immunotherapy cohort (GSE35640), all of which illustrated that the high-risk group was resistant to anti-cancer immunotherapy. This evidence concerns the gene CTLA4 and cancer.